TokenPost·
Vertex Pharmaceuticals Raises 2026 Revenue Guidance After Mixed Q3
The new range tops out below the $13.28 billion consensus estimate, as quarterly revenue beat estimates and the bottom-line result missed.
More news
- TokenPostTutor Intelligence Raises $75 Million in Series B to Expand Robots
- TokenPostApple Forecasts Lower December-Quarter Gross Margin After Record Revenue
- TokenPostDivided government after US midterms could curb policy moves but raise foreign conflict risks
- TokenPostUkraine’s D·Vision Receiver Lets Troops Watch Russian Drone Video
- TokenPostWintermute’s Hyperliquid Shorts Carried $3.35 Million in Unrealized Gains
- TokenPostTether CEO Says Firm Holds About 150,000 Bitcoin (BTC)